In short
Podcast Episode Notes: CNBC's "Fast Money" - The Latest U.S.-China Tit-For-Tat… And Fast Money’s Obesity Week Continues (12/3/24)
Episode Overview In this episode, hosted by Melissa Lee with a panel of expert traders, the discussion focuses primarily on the escalating trade tensions between the U.S. and China, the implications for investors, and a continuation of coverage on the obesity drug market. Key topics include tariff threats, company strategies, and emerging biotech solutions for weight loss.
Key Topics Discussed
- U.S.-China Trade Tensions
- Current Developments:
- Beijing has retaliated against U.S. chip export restrictions by banning sales of critical minerals, effective immediately.
- This escalation follows the Biden administration's moves to limit exports of chips and related technologies to China to slow military advancements.
- Market Impact:
- The traders discuss the potential effects of these tensions on U.S. companies, particularly those reliant on China for revenue.
- Concerns are raised about the long-term implications for multinationals operating in China, with particular focus on brands like Apple, Nike, and Starbucks.
- Investor Sentiment:
- The panel expresses mixed views, with some seeing opportunity in the sell-off of Chinese stocks, while others caution against the risks posed by geopolitical developments.
- Technical Analysis on Chinese Stocks
- Expert Insights:
- Chartmaster Carter Worth advocates for buying Chinese stocks despite the current tensions, presenting a bullish technical analysis that indicates a potential upward trend.
- He provides specific stock recommendations, including Alibaba and Tencent, emphasizing the importance of market timing and technical patterns.
- Bitcoin Investments
- MicroStrategy's Moves:
- MicroStrategy's CEO is increasing the company's Bitcoin holdings significantly, showing commitment to the cryptocurrency.
- Discussions revolve around the implications of this move for Bitcoin's price trajectory, with predictions of Bitcoin potentially reaching the $100,000 mark.
- Obesity Drug Market
- Altimmune's Experimental Drug:
- The CEO of Altimmune discusses an innovative obesity treatment, pemvidutide, which combines GLP-1 and glucagon to aid weight loss and improve lipid profiles.
- The drug's potential benefits include preserving lean muscle mass, which is particularly significant for older adults.
- Partnership and Commercialization:
- The panel discusses Altimmune's need for a commercial partner to successfully bring the drug to market, identifying crucial steps in their strategy.
Key Takeaways
- Invest in China?: The panel debates whether current political tensions represent a buying opportunity for investors or a risk that could impact stock performance significantly.
- Bitcoin's Future: MicroStrategy's aggressive Bitcoin strategy showcases confidence in cryptocurrency, but the risks associated with such high leverage are acknowledged.
- Obesity Drugs are Evolving: Biotech firms are innovating beyond weight loss, targeting comorbidities associated with obesity, presenting new investment opportunities in the health sector.
Closing Thoughts The episode emphasizes the need for investors to stay informed about geopolitical events and market dynamics, especially concerning U.S.-China relations and the healthcare sector's emerging trends. The discussions provide a mix of caution and optimism, encouraging careful consideration of market opportunities amidst volatility.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:00Live from the Nasdaq market site in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. Time to buy China from tariff threats to trade restrictions. There seem to be plenty of reasons to tread lightly in the region, but the chartmaster says buy. He will lay out the case. Plus, betting on Bitcoin. MicroStrategy CEO is expanding his exposure to the crypto in a big way. What it says about where the coin is heading and how soon it could hit 100K. And Obesity Week continues with the CEO of Biotech Altimmune. How its experimental weight loss drug sacks up against the competition and where the stock goes from here.
0:33I'm Melissa Lee. Coming to you live from Studio B at the NASDAQ on the desk tonight, Tim Seymour, Dan Nathan, Guy Adami, and Danny Moses, the founder of Moses Ventures. We start off with the latest tit-for-tat in U.S.-China trade relations. Beijing retaliating against the latest chip export restrictions by announcing it will no longer send certain critical minerals to the U.S. CNBC's Megan Cassell has got the details on this. Megan. Hey, Melissa, that's right. A real ratcheting up of trade tensions with this move today from China to ban the sales of these rare minerals to the U.S. effective immediately.
1:04Now, this, of course, was a response to the Biden administration's move on Monday to restrict the export of some chips and chipmaking equipment and software to China in order to slow Beijing's development of advanced weaponry and AI systems being used by the military. Beijing today rejected the U.S. justification of that move, saying Washington has generalized the concept of national security in recent years and abused export control measures. Their response today represents a real significant stepping up of these tensions, not entirely unexpected as they did begin laying the groundwork to make this move possible over the past year.
1:37But it could only be a first step given, of course, the additional tariffs that Donald Trump is vowing to impose when he takes office. The critical minerals being targeted have broad military uses. They're used to make weapons, but they're also in a number of consumer goods, phones, computers, cars, all industries, Melissa, that could feel an impact as this trade and tech war between the U.S. and China starts to heat up. Melissa. All right, Megan, thank you. Megan Casella. It is of note that, you know, these metals have not been shipped to the United States for a couple of years now. So it either indicates that companies have moved away or they've drawn down stockpiles that were built up before.
2:13But not either way, tensions are getting worse. Well, we talked about this last night and we talked about, I think, for the most part for our investors right now, the question is, what's the impact for U.S. companies? So when you talk about U.S. miners. No, of course, they're not on the ground in China. And yes, there's no question that probably for the last 20 years, and we've done it here. Remember the Unical deal where the Chinese were coming in to buy? I mean, this goes all the way back in time. I wouldn't be that scared off by these headlines. I do think also the last couple administrations, including this one, going back to their first one, were thinking about how do we secure rare earth and some of these important minerals on these shores.
2:48So it will lead to some squeezes here. But I think the The more important dynamic is what Eunice Yun was saying on our set yesterday. Not an as live guy. No, she was actually here. She was here in person, and it was great. And she reinforced the story that the Chinese are less concerned about external interpretations, or at least really, more importantly, policy as it affects the economy, when in fact they care a lot more about policy, what that means for securing power, the Communist Party, for social control. And that's really potentially risky for U.S. companies. They're playing the long game, so they don't care what the near-term impacts are of that long game.
3:23And we also mentioned the yuan at the lowest level now in a year. And look at the move since October. It's actually pretty startling how quickly it's deteriorated. And, you know, you go back to August 11, 2015, when they actually announced the devaluation of the yuan. And by February of the next year, our equity markets felt it, to Tim's point. So nobody's paying attention to this now. I think they should. J.P. Morgan had a note on it, as we said last night. And I think to your point, Tim's point, it's not so much what this means because maybe it's not a big deal. It's the ratcheting up of the rhetoric that's important.
3:55So prior to the election, it even posts, there's been a lot of stimulus in China, right? They're trying to just spur up demand there. Obviously, we know there's going to be issues with tariffs with Trump next year. They're getting ahead of it. But I have a question for Guy. Guy, on the periodic table. Well, Danny, she asked the questions. On the periodic table, gallium and germanium, do you have any idea what the numbers are? I believe they're 128 and 131. No, but I'm saying it's not important right now, U.S., but it's just rhetoric. And I think it's just noise right now. And so I know we're going to talk about what you should do with the China trade in general.
4:23But I think it's just noise. I think a lot of U.S. investors, to Tim's point, have a hard time kind of like figuring out where this kind of lies. But when you think about like a whole host of other U.S. brands, this is what I want to focus on a little bit. You know, if you think about Chinese demand for U.S. brands, they're going down. I mean, make no mistake about it. iPhones only grew like by a half a percent in Q3 last year in China. Well, they're third place. They've lost five points in market. And you know what? IDC is tracking this. And, you know, like, you know, Android phones grew 6 % year over year.
4:53And so iPhones are not growing. So, like, if there's some nationalistic tendencies towards some of this stuff, I mean, I think that's a bigger problem for U.S. monthly nationals. I mean, we've talked about this before. Soft boycotts, you know, sort of the informal boycotts of people on Weibo, you know, voicing their unhappiness with U.S. brands. I mean, already U.S. brands are having difficulty. And then you want to layer this on top of it? I think it's a problem. But I got to be honest. I thought this was going to be a problem two years ago or so when the rhetoric around Taiwan started getting ratcheted up and nothing really has happened.
5:24But it hasn't gotten better. In some ways, it's gotten worse. Now, what's remarkable to me is our markets have not cared one iota. But there are things out there that I think we should be paying attention to. And you wonder what companies are in the crosshair. Apple is the biggest one without question. I mean, Nike has its own issues without question. But, you know, Nike is a stock that's more than half of what it was three years ago. And obviously, that's a big China play. Oh, there's Starbucks. There's McDonald's. There's Nike, as you mentioned. Yeah. Yeah. I mean, I think that that's a story.
5:55I think also investors are thinking about as we get to the end of the year, this is also that time you start planning for 2025. What's going to be different? We came into 24. And I bet we would have all said that we did all say. And I bet even Danny was here. And he said, we're worried about geopolitics. Well, geopolitics, I would say this is one of the most spectacular years and spectacular. I don't necessarily mean that in a positive way in 24. And yet geopolitics didn't do anything. Markets, we know what they've done. So it's a question of U.S. exceptionalism. Is this the place you're going to continue to see to invest?
6:25You know, right now you've got a no confidence vote in France. You've got problems around the world. You've got dynamics that I think are going to put even more pressure. But I get back to guys 2015 deval. What you're hearing from all these companies is we're not going to be afraid to let our currencies truly float. And the ultimate elixir for any economy that's struggling is let their currency go. And so that's going to be very good for Americans traveling around the world. It's going to be good for American buying power. But it's possibly going to be something that I think we have to worry about for multinationals.
6:52Yeah, and it's something that Donald Trump has spoken out against in the past in terms of the strong dollar. A weak dollar is very helpful for U.S. companies. U.S. multinationals play a key role in the economy in China, whether they like it or not. And they can ill afford, I think, to really go into this type of back-and-forth rhetoric without implications, because if they start kicking U.S. companies out of that, if that were to happen, that's only going to make it worse there. Yeah, you know, Tim just used the term American exceptionalism. I mean, you know, pull up a chart of Apple right here.
7:16It's rallied 10 percent from its lows in early November. And here we just said that iPhones aren't growing. This is a product that's more than 50 percent of their sales. So when you think about some of the money that's coming out of these other places, it's clearly coming here into the U.S. And, you know, Apple trades it 33 times this coming year's earnings. I don't know if it's ever traded like that at this sort of growth. I mean, it's really talking about single digit growth. And let's be clear. In June, when the stock was massively underperforming, OK, like the broad market, I think it was up less than 10 percent versus an S &P that was up like 15 or 16 percent or so.
7:50All the analysts could talk about is this massive upgrade cycle that was coming this fall. It's gone. It's not happening. Apple intelligence is a freaking zero. I mean, like seriously. I'll say this. I agree the refresh is slow to happen. It's going to happen. And it was going to happen anyway, largely. But what all the analysts are also saying is we're in the broadening of the AI trade. And the AI trade, which is now into software, and we're seeing that, I think Apple is perfectly positioned, whether it's Apple intelligence or not. I mean, they are truly the use case. There certainly will be that follow through.
8:19That's partly what the market is rewarding right now. And I don't think the market that move from 185 to break through that two year resistance. I don't think that was on a refresh. What if I said to you, though, that Apple would not have an AI product at all in China? Because all China has to do is say you will not have a partner for AI because Apple needs that local Chinese partner for AI. So if there is no AI there, what drives the upgrade cycle in China? Nothing. The whole story in China is Huawei and Xiaomi. And they're working on their own chip. They're working on their own AI capabilities that will be on the edge.
8:53And we have no reason to believe that their phones won't be much better than that of Apple's. I don't I'm not doubting that. But I'm just saying for bulls, if they're counting on some sort of upgrade cycle, help from China, it may not come if the Chinese government decides no AI partner. Haven't we stared China risks for Apple in the face for a year? I mean, I guess, you know, I don't want to belittle the impact there. And if there was a headline tomorrow, we know what Apple would do. I think we all recognize for China, there's an India where, you know, where smartphone penetration is 3.3 percent, where the market share is.
9:26I mean, there's there's a lot of other markets for them to grow. That three billion installed base right now, if you remove China, it would be it would be a big impact. But I don't think it stops. You know, we couldn't go 10 minutes without talking about gold in this conversation. And, you know, it was announced that China stopped purchasing gold in April of this year. And the market took that as OK, they're done. Maybe that's the end. And now Goldman Sachs just put out a note that, wait a second, maybe they've actually been buying gold in the over-the-counter market that really is sort of opaque.
9:51And they thought another 60 tons worth of gold might have been purchased. So you tie this all up in a bow. China, you know, yuan going low, all this rhetoric. All roads lead to gold, despite the fact that it had a rough couple weeks. It got back on its source over the last couple days. Yeah, gold is one of my favorite investments right now. It has held up in the face of the dollar strength. I know the dollar's come in the last few days, but it held up. And I think with all the geopolitical stuff going on around the world, it's a place to be. And it feels like it's about to take off from here for sure.
10:20All right. Meantime, the chart master put out a note this week saying it is time to buy China stocks. Back in October, he was a seller of China mega caps. Let's bring him in now for the latest technicals on this trade. Hey, Carter, what are you looking at? Sure. Before we look at the charts, you know, it's been a bit hysterical, right? In October, you had record inflows. And we're just having reports now that November has seen record outflows. Often it's right to take the road less travel. That was the thought in October. Fade the hysteria. And now I think we've got the equal and opposite circumstance of people abandoning it just as aggressively as they were embracing it.
10:54So let's look at the charts. My thinking here is to buy this sell-off. Here is a five-year weekly chart. No drawings, no annotations, no judgments. Next chart has some of those. And what we know is we have that very optically clear double bottom. You have the euphoria, that spurt there in September and October. At that point, trading farther above the 150-day moving average at any time on record. And now this big giveback. And I think that's the flag, if you will, the retracement to buy. Let's look at a stock or two. Obviously, the biggest or most important is Alibaba. And you have a great circumstance here, a sell-off to the penny to a rising 150-day moving average.
11:35Look at Tencent. You also have a similar circumstance, right, different shape, torque, character, but same circumstance, the big September-October move, and then this give back to the level from which it broke out, and again, to the penny, to the$100 and today moving average. I'm buyer of both of those, and I'm buyer of FXI. All right. Carter, thank you. Carter Braxton Worth of Worth Charting. As a trade, are you a buyer, too? Agreed. And I wasn't born with a crystal ball, but I'll say this. There's going to be, over the next couple weeks, David Tepper's going to be on the network. Joe Kernan or Becky's going to ask him about the China trade, and he's going to say, I'm still in it.
12:11I still believe in it, despite the fact that it has round-tripped the entire thing. And Tim Seymour sat here a month a half ago when Alibaba was 117. He said, you know, I'm long in stock, but I'm absolutely selling calls against it. That was prescient because it's round-tripped as well. But we have filled in all the gaps that are created to the upside. That trade is not over. I agree with Carter Worth. The things that worry me most about owning Alibaba are not related to the bottom-up story, and they're not really related to China macro. It's probably – so to the extent that China macro could be corporate governance dynamics, I don't know what they're going to do to Alibaba next, although I think they've already kissed the ring and been through that, you know, yeah, who's your daddy.
12:47And I think the story of a company with 45 percent of their market cap and cash, the story of a company that I think continues to at least talk about spinoff of assets, This is some of the parts. This is an earnings multiple. That K-Web, which is the collection of the largest Chinese Internet name. So if you don't want to play just one name and you want to diversify, that's still up 21 percent from the lows in September. So even after this move. So guys, right. And it's nice that he pats me on the back for selling some upside calls. I mean, bottom line is I'm still in Alibaba. And so collecting some premium is great.
13:18But I believe in the long term trade. And I will say there's a lot of people patting themselves on the back. And they're right, which is what Carter said. A lot of people said, fade this move. It's not big enough. It's not big enough. I think they're I think they're also waiting for Trump to take office, frankly, before they really unleash. Why would you do it now? Why would you bring out some of your biggest stimulus when you really don't know what's actually going to happen? Being zebra, the baba. Yeah, it is. It hasn't been a great trade to your point, Tim. But, you know, this goes back to what you were just saying about, like, the other parts of the world.
13:47The sentiment is so bad. The valuations are so low. Where are you going to get alpha in this market? Are you going to continue to buy into what might be perceived as a valuation bubble here in the U.S.? Are you going to look at the FXI? Are you going to look at EEM? I'm just looking at EEM, Taiwan Semi, Tencent, Samsung, Alibaba. That's some good exposure that some underperformers, some things that Taiwan Semi should be up the way it is. So EEM looks interesting to me, but I also like the K-WIP. It's not just Asia. It's Europe. I mean, a lot of these markets around the globe have been left for dead, so to speak.
14:16And the U.S. feels like it's a little bit overrun right now, and people aren't paying enough attention to the global markets in general. Let's talk Tesla now. The rally taking a breather today shares down a percent and a half after new data showed deliveries from its Shanghai factory fell for the second month in a row. Yet our guest trader tonight, Danny Moses, who's been short Tesla at various times in 2016, isn't betting against it right now. And for the viewer, you know, you're constantly trading. So keep us updated on where you are. Listen, I first got into the trade after the SolarCity deal was done in kind of late 2016 into 2017, thinking that, wow, that was an awful deal.
14:50I'm going to get into the stock now. Short, off and on for the last few years. The first quarter this year when they reported. Who was the CEO of SolarCity at the time? His cousin. Yeah. Exactly. He won that court case also. Okay. Right. So fast forward to the first quarter this year. It had just started to trade on fundamentals for the first time in a long time. It was hanging around$140,$150, right? So you felt like, okay, the quarter was bad, right? What happened? Promise of autonomous day in August, which ended up getting pushed out to October. Flies to China to get some regulatory relief on certain things.
15:18And lo and behold, attaches himself to Trump to make all the other stuff go away. When the story moves from non-fundamental to technical in those nature, that's when I leave a story. And we talk about it on the podcast a lot, giving updates there. But to people that are listening now, it's very difficult, certainly to short a name. He is not trading on fundamentals. It's also hard to go long a name when it's all on promises. And I'll say this about Musk. He's promised shareholders things in the past that never came to fruition, was given the benefit of the doubt. He's now talking about cutting$2 trillion, you know, from the U.S.
15:49budget, being able to basically improve the budget. And you're not going to be able to do that. So it's one thing to mess with shareholders. It's another, in my opinion, to mess with the American citizen. So we'll see. But it feels like it's moving from the corporate world, right, you know, into the U.S. Don't mess with America, man. Sorry, I had to go there a little bit to surround that out. Well, I mean, like the question is, does Elon Musk want to take away a lot of the safety net services of people who can't even afford Teslas? You know what I mean? Like, I just think this is an uncharted territory where we are right now.
16:16It's one thing to take Dick Cheney, who is the CEO of Halliburton, and put him in that sort of seat. And, you know, it's a very transparent sort of thing. What's going on with this doge is going to be the it's not going to be particularly transparent. This is interesting because it does go back to a trade because you you think about who this alienates in terms of Tesla buyers. Right. And so for everybody. who loves where Elon Musk stands, there's probably somebody else who doesn't. It's on the opposite side. That might be true for like a Coca-Cola where you talk about brands that have alienated.
16:45I'm not certain that holds water in terms of Tesla in their base. Maybe I'm 100 % wrong. And quite frankly, I don't even know if it's about auto sales anymore. Anyway, so I get what you're saying, but I don't think that moves the needle. Think about this. Other than this comp package thing that happened yesterday, the only court case that Musk really ever lost was that he was forced to buy Twitter, right? What happened when he bought Twitter? Only good things happened for him because he used it as a platform to spread whatever kind of information to get what he wanted. And every single investigation that might have been going on is now gone.
17:15But to Dan's point, you should be concerned as U.S. consumer. If you get approved for FSD when it's still supervisory, it's a danger. And that's not a Tesla comment. That's just in general. So that's the stuff I'm watching for now. It has nothing to do with the Tesla stock. Well, again, we know there are industries and the auto sector. The irony here is that actually the big three or maybe the big two now don't necessarily love what should be support of Detroit. And again, removing I know it sounds crazy, but removing EV subsidies and making it more expensive to build an EV car is not good news for GM, who's not given any credit for their ice business.
17:49So GM shareholder, I actually think some of this is sentiment that will just work its way through. But, you know, and look at the steel sector today. I mean, there's all these conversations about what, you know, keep it in America, build it in America, no foreign partners for America. Not great always. Hey, really quickly, I know Mel wants to move here. They also want to cut the CFPB. So we're talking about autos. We're talking about this sort of thing. There's a lot of implications if you cut that. That is meant to protect consumers from financial, you know, fraud or whatever. Exactly. Coming up, we are watching Salesforce after our shares on the move after the latest report.
18:23But the details in numbers from that quarter and what CEO Mark Benioff had to say about the results next. And from Salesforce to cellular, shares of AT &T getting a boost on the back of its investor day, how they're putting their cash to work and the earnings guidance sending the stock to multi-year highs. Don't go anywhere. Fast Money is back in two. This is Fast Money with Melissa Lee right here on CNBC.
18:54Jim, while Salesforce now is running its whole company on AgentForce, and all of our support is on AgentForce, and many other aspects of our business are now on AgentForce, I would really challenge you to go to Microsoft's website, talk to any of their employees, see how they're using it all. I don't even think they can use Copilot inside Microsoft. So this is an opportunity for all customers to go to another level using this incredible capability. That was Salesforce CEO Mark Benioff talking with Jim Cramer about his company's AI push. You can get to the full interview top of the hour. Shares of the cloud company jumping up almost 7 % despite a mixed quarter.
19:32The conference call is underway. Seema Modi's got the latest. Seema. Well, Melissa, enthusiasm around Salesforce's AI offerings seems to be paying off, with the company lifting its fourth quarter sales and earnings guidance. CEO Mark Benioff on the earnings call saying the real excitement is around the rise of digital labor. He said for many years the company helped customers manage data and analytics, but now the company has created a new market that is so much bigger than data management, the market for digital labor with the rise of AI agents to help customers compute complex data models to serve their end user.
20:05He also made the point that these AI agents will only enhance human capabilities. A strong street reaction to earnings and even before the results came out with Wedbush remaining overweight, a$3.75 rating. Piper Sandler upping its target to$3.95. But keep in mind, Salesforce is not the only software cloud company leaning into AI agents from ServiceNow, Asana, Oracle, among others. It is, in fact, though, fueling the software trade with software stocks, on average, outperforming chip stocks since the U.S. election. Melissa? Seema, thank you. Seema Modi with all the details on CRM. Is this the handoff that we've been looking for?
20:44And this sort of reminds me of Meta in that, you know, they're creating an AI. They've got an AI product, but they're also using it internally to improve their own metrics. Listen, the promise of AI is really to take out customer management, you know, sort of things. And this is what this company does. So we were just talking about the valuation in Apple relative to its growth. This company is expected to grow earnings and sales next year about 10 percent. trades at a very similar multiple to Apple at 30 times. And you could say, well, that's probably really conservative, those gross estimates, if they deliver on the things that Benioff was just talking about.
Read the full transcript
21:15So to me, this one's interesting, but it's trading at all-time highs, up$20 in the aftermarket. I think this one feels safe here. I think it was second straight solid quarter where free cash flow growth is really underpinning part of this. Also, the question is 8 % year-over-year growth. C-Pro, which grows at about 10%, which is at least where you want to see more growth and you got a little more. It just gets back to the multiple here. But I do think, and we've had this conversation in the last month, I think software is how you're seeing the delivery of AI. It's exactly what you're both saying, which is that it's companies themselves that are getting leaner and meaner, which is one of the things Savita said in terms of what it even means for the industrial complex.
21:50But, yes, I do think you can own this one. Look what's going on in Intel hardware versus Salesforce software. Investors are looking for growth, places to go that don't require lots of CapEx, obviously. So I think they're a beneficiary of other names coming up. It was real quick. It was great that she was here last night without question. The markets, I'm not a hater. I'm not a hater. They missed on EPS. They beat on revenue slightly. The one thing people looking at are margins were better without question. The guide was not good. It now trades at 35 times next year's numbers. I mean, good for them telling a great story.
22:25But this got itself expensive on the back of this. All right. We've got a news alert on Amazon's Black Friday NFL game. Julie Borson's got the details on that. Julia. Hey, Melissa. Amazon's Prime Video's second Black Friday game delivered 13.5 million viewers. That's an average audience increase of 41 percent over last season's inaugural Black Friday game. Now, this marks the second largest viewership game of the season for the NFL, a 42 percent jump for the November 7th Bengals-Ravens game, which shows ongoing awareness of the NFL in its third year with regular season games on Amazon. It also comes after Thanksgiving Day games had the highest viewership on record, up 6 % from last year.
23:05So the NFL continuing to deliver, Melissa, for Amazon as well as all of its other broadcasters. Any indication as to how much shopping was done during that game? You know, we don't have that data just yet. But what we know from last year is that when people were watching the game on Amazon, they were also engaging with ads. This year, we interviewed Amazon's Jay Marine about all the new ways they were offering interactivity in the ads, making the ads shoppable, both with QR codes and with the ability to shop with your remote. So you can bet that they were finding lots of ways to take that viewership and make sure that they were spending money on Amazon.
23:43All right, Julia, thank you. Julia Borsten, zero chance guy was buying anything online, let alone streaming. With his remote. With his remote. I mean, there's things that you bought with your remote, but probably that was 10 years ago. Seriously, I'm not going to say what. I swear I'm not. You can buy things with your remote control. Yes. So the thing you point at the screen. Yes. And that's the world we want to live in. If you have a tube TV, though, Guy, I don't think you can do it. The cable box that's next on your side table with the three rows. The brown one, yeah. It's no surprise that Thanksgiving football was at records because people don't want to talk with each other anymore in this politically diverse landscape that we find ourselves in, number one.
24:22Number two, Amazon is a stock I think collectively we liked. I mean, you know, outside that one little misstep they had for about a six-month period, it's been an amazing stock, Don. I think you stay with it. All right. There's a lot more Fast Money to come. Here's what's coming up next. AT &T looking like a wireless winner. Shares surging on the back of the company's investor day. The cutting-edge tech they're doubling down on next. Plus, Fast Money's Obesity Week continues with the CEO of one biotech company hoping to slim down the competition in the weight loss drug space, their latest results, and the key data that may set them apart.
24:58You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.
25:11Welcome back to Fast Money. AT &T shares hitting their highest level since 2021 today. The company unveiling a three-year plan to return more than$40 billion to investors through dividends and share buybacks. CEO John Stanky also telling Squawk on the street that AI demand is driving the company to double its fiber optics business. He said there's also a—well, let's listen to what he has to say. If you think about AI in particular, just think about how sensor technology, the number of cameras that are now out in somebody's life, around their home, in their car, in a store, and all that video needed to be shipped up to the network in order to be analyzed using AI algorithms, that alone is going to drive an incredible amount of upstream bandwidth and demand on a network.
25:53And that's why we think these investments are really appropriate to make right now and puts us in a unique position. AT &T also saying at today's Investor Day it expects free cash flow to hit$18 billion in 2027. So a lot of capital to be returned, but also enough to invest further in its fiber optic network to satisfy this demand. Well, their investments got them in trouble in the first place. With that said, I mean, it's been the move from$13 has been unbelievable. Tim has talked about this as well. With that said, if you'd put up a 9, 10-year chart, we are right at a downtrend level. So this is a huge level to break through.
26:28I'm not sure it's going to get there. The flip side of the coin is T-Mobile continues to do everything right. And it's within a dollar or so of its all-time high, like many stocks. So I think it's still T-Mobile's world to live in. No question, T-Mobile's been the play to have even after, you know, even this year. But say this about AT &T and say this also about the, call it the mercenary or the predatory nature of the competitive landscape. And what's really, what do you call it, a tripoli? What's, what do you, what do you, not an oligopoly. What are three? What are we doing? How are we, what's an industry with?
26:58Triumvirate. Triumvirate. I don't know about triumvirate. I think it's, I'm going to go tripoli. Twitter fans, you can correct us. I have no idea. The point is that they've now, there's three companies, and I'm not saying they're colluding, but they can slowly raise prices, and they're sticky, and they're holding it. And AT &T, you don't have an investor day unless you have good news. $40 billion they're going to give back in terms of divs and cash buybacks. I think you stay long. Two legacy companies have reinvented themselves over the last few years, Disney and AT &T. AT &T is selling off the bad assets, focusing on growth areas.
27:28Disney, to me, doing the same exact thing. And so two areas, two names, I think, that are getting bought by investors. or two. Coming up, Obesity Opportunity, how Alt-Immune's experimental drug could have a competitive edge over Zep Bound and Wigobi while also treating liver disease. The CEO will join us straight ahead as Fast Money's Obesity Week coverage continues. Back right after this. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
28:04Welcome back to Fast Money. The S &P 500 and Nasdaq both closing at fresh records today while the Dow lost about 76 points. Shares of United Airlines taking a breather from its recent rally. Shares lower today, but still up more than 132 percent in 2024. CEO Scott Kirby telling our own Phil LeBeau this morning the company expects to post its best December revenue on record. Shares of U.S. steel down 8 percent. President-elect Donald Trump reiterating his position, opposition, I should say, to the$15 billion takeover bid by Japan's Nippon Steel. Trump posting on Truth Social that he does not want the American resource company to be owned by a foreign company and that he will block the deal when he takes office.
28:40U.S. deal down 23 percent this year. FedEx and UPS also lowered today. Analysts at Bernstein downgrading FedEx to market perform, lowering the price target to 316. From 337, the firm citing execution, event and policy risk. And a few mega cap tech names hitting fresh record highs. Apple and Meta both trading at those levels. Well, Altamune bucking the biotech sell-off over the past month, soaring 30 % in that time while the XBI biotech ETF is down slightly. The company now gearing up to put its experimental obesity drug to the test in a phase three trial, also set to give more data on how it can treat mash liver disease in early 2025.
29:16For more, we're joined by Altamune CEO Vipin Garg. Vipin, great to have you with us. Thank you for having me. That drug, pemviditutide, if I can say it. If you can sort of give us an overview, it's now just entering phase three. And as I understand, it will be 5 ,000 subjects across four different sort of trials that will explore different attributes of the drug. Can you give us a status report on where that stands now? Absolutely. So as you said, PEMV-DU-TITO, we call it PEMV for short. It's a dual agonist that combines GLP-1 with glucagon. And the benefit of that is that in addition to appetite suppression, which is produced by GLP-1, glucagon is acting as increasing energy expenditure.
30:07As a result, we are able to get a better lipid profile in these patients. See, the whole obesity market, as it evolves, it's going to be more about not just about weight loss, but what else do you bring to the table? What are the comorbidities of obesity that you're able to treat? And that's where pemvidutide shines because of the glucagon component in the drug. It's having direct effect in the liver. It is defatting the liver. At the same time, the serum lipids are improving and blood pressure, all of which are risk factors for cardiovascular disease. So people really don't die of obesity. It's the cardiovascular disease that has to be treated in order to improve outcomes in these patients.
30:48And the way we've designed our four trials in our phase three program really reflect that those benefits of pembedutide. These trials are specifically designed to take advantage of glucagon component of the drug. Can we also talk about preserving lean muscle mass? Because that is a major complaint, particularly in older people who might be more susceptible to losing lean muscle mass. That's more of a problem, particularly if your bones are weakening. weakening. In phase two, you had some very interesting results. 50 patients were in phase two, but 21.9 % of the weight loss there was attributed to lean muscle mass.
31:26But that compares to a lean muscle mass loss of up to 40 % in Wagovi at the end of 68 weeks, which is a longer period of time. But still, can you talk to us about how that compares, PEMV compares to sort of the other drugs out there that are trying to not make you lose lean muscle mass, the myostatin inhibitors, how are they different? So people are talking about combining different therapies. Here, what we are doing by adding glucagon, we are already getting that benefit because what glucagon is doing, it is increasing energy expenditure and actually turning the metabolism to fat burning rather than protein or carbohydrate burning.
32:08So as a result, we are losing more fat mass as opposed to losing protein mass and carbohydrates. And that has knock-on effect. The benefit is that we're seeing class-leading lean mass preservation. This is really important in people over 60 years of age, in post-menopausal women, as well as in people with sarcopenia. A large number of patients will benefit from a drug like this. And really, we don't need to combine two drugs to get the same effect. We can, with the same drug, we can get preservation of lean muscle mass. In your earnings call, Vipin, somebody in management said that you're going to need a commercial partner to commercialize the drug.
32:48And so I'm wondering how you think about that roadmap and what that partnership could look like for you. Yes, our strategy is to secure a partnership around obesity. As far as MASH and other indications are concerned, we are moving full speed ahead with those. and those discussions, those developments are moving forward. So ultimately, in order to commercialize in a large obesity space, we are going to need a partner and we are seeking that. Will you be independent in this partnership or does this partnership include the possibility of being bought? Well, there are many different ways these partnerships can be structured.
33:27It's hard to define that ahead of time, but depending upon how the partnership comes together, Our goal is to find a partner that can bring full value to the asset, both obesity, MASH, and other indications. If it's just obesity, then it'll be a partnership. But if it's the whole molecule, it could be something, a different kind of structure. Okay. Vipin, thank you. Vipin Garg of Altimmune. And a reminder, you can catch more special Obesity Week coverage right here on Fast Money All Week. Starts at 5 p.m. Eastern time each day here on CNBC. What's the trade here? Well, it's interesting. I know Steve Grasso talks about this.
34:01There's a$650 million company right as we speak. It might be more now. It's probably up in the after hours. They have a quarter of that in cash and cash equivalent. So that suggests they got some runway here. They probably burn about$20 million a quarter or so. It's an interesting story. But you asked the right question. You know, are you going to be able to go this alone? And he answered it. And the suggestion is that I think they're open to a partnership. So it becomes an interesting stop. I thought the suggestion was that he was open to everything. Or that. Which is interesting. What's been kind of interesting for me from a price action is to watch Lillie bounce.
34:32Lillie's actually bounced quite nicely in the last, you know, call it week or so. And I think where expectations got back to a little bit more of a reality. I think a lot of people traded out of this name. I know it's still a crowded trade. But the Lillie over Amgen move in the last week, I would reverse that. Again, I think Amgen was overdone. All right. We got a news alert on President-elect Trump's pick to lead the DEA. Chad Chronister pulling himself out of the running, saying in a post on X to have been nominated to serve as administrator of the Drug Enforcement Administration is the honor of a lifetime, but went on to say there is more work to be done for the citizens of Hillsborough County, Florida, and a lot of initiatives I'm committed to fulfilling.
35:08This is Trump's defense secretary pick. Pete Hegseth comes under increased scrutiny. All right, coming up, BlackRock making a$12 billion bet on the private credit market. The details on the deal and what it could mean for investors next. And talk about a big bet. MicroStrategy digging its heels into the crypto stance and scooping up even more. Bitcoin, what CEO Michael Saylor had to say about the move. All that when Fast Money returns.
35:40Welcome back to Fast Money. BlackRock pushing deeper into the private credit boom, buying HPS investment partners for$12 billion in stock. Leslie Picker joins us now with all the details. Hey, Les. Hey, Mel. Yeah, the combination creates a private credit behemoth with$220 billion in client assets, which would make BlackRock the fifth largest manager of the asset class, according to PitchBook. BlackRock said in the release that it expects the private credit market to more than double to$4.5 trillion by 2030. That bull case is driven by the notion that market forces and technology and regulation are all pushing activity toward private credit, which some see as a more efficient way of doing business than syndicated lending conducted through banks.
36:23BlackRock is not alone in this thinking. State Street told the Financial Times last month that it's looking for acquisitions or minority stakes to fortify its private credit offerings. Such tie-ups have become increasingly common as well at asset managers, insurers, even large banks. But skeptics are plentiful. Some say the burst in private credit popularity is indicative of a bubble. Others say this newfound debt load will lead to a reckoning in the next major downturn. In the meantime, though, publicly traded private credit firms like Blue Owl and Aries see big returns year to date, outperforming BlackRock, which did gain on today's announcement up about 2 percent.
36:59Melissa. Leslie, thank you. Leslie Picker. We've got a skeptic right here on the desk, in fact. A skeptic. I think it's great to raise money and put it to use in the private credit market. I can think back to 2004 and 2005 during subprime. What happened was there's normal credit cycles that always occur. Subprime mortgages default, and they go delinquent over a period of time. The 228 mortgages, the 327, the ninja loans all made it seem like this time is different. So what happened was everyone dove in insurance companies, pension companies, like, oh, we can get a nice yield, very little credit risk.
37:30Right now, private credit is north of$2 trillion. It's not being monitored because they can't monitor it, the Fed, Treasury, because you can't really see it. It's gone off the banks. We know why. And there's nothing wrong with what they're doing. All I'm saying is you see these PIC loans, payment in kind for interest, right? You see these modifications occurring. At some point, it's going to catch up, and the performance of these loans will start to diminish. And so all I'm saying is people be aware. And listen, it's having an effect on credit spreads across the entire market, just this thirst for yield in general.
37:58So people just need to be aware. Somebody's doing nothing wrong. Great acquisition. It's going to look great. You won't know for years if this was a bad decision or not, but just something I'm watching for. Well, and if you look at where high yield OAS spreads are, so you're basically as tight as you've been since really right before the market of the great financial crisis started to unwind a lot. And what Danny's saying, I think, is important, too, because if you think about the world of subprime and Danny was as close to it as anybody, the government and the regulators were actually pushing people into it.
38:28They were pushing the players. I mean, there was a time when this was actually in their best interest in the same way that essentially regulators are fine with private credit, have been pushing them there. A lot of the banks haven't wanted to go there and they've been filling a void. So it's been a good thing. But you do have to be careful. And I just say again, we talk about those risks that we came into 2024. And certainly, you know, in 2023, we thought that as long as higher for longer, at some point, this was going to have a big impact on private credit markets. And it hasn't. So great. They're just bigger now.
39:01Commercial mortgage-backed securities, also known as... CMBS. Yes. How clever. Always a good acronym on Wall Street for products. Always a good acronym. 10.4 % delinquency rate, the highest we've seen now in 11 years. Another thing that nobody's talking about. It's not like it's been creeping up. It's been moving up in an exponential fashion over the last few months. Coming up, MicroStrategy, digging even deeper into the crypto trade. Why the CEO thinks there's a lot more upside left for Bitcoin? And when can we expect it to finally cross the 100 ,000 mark? We'll debate that when Fast Money returns.
39:41Welcome back to Fast Money. MicroStrategy buying another$1.5 billion worth of Bitcoin over the past week. The software company-turned-Bitcoin holder now has over 400 ,000 coins on its balance sheet. That is worth almost$40 billion. So what do we make of this, Dan? I've never seen anyone committed to something. You take the biggest religious zealot. I mean, listen, you've got to give the guy credit. I mean, you've got to his commitment. And I wonder if he would like to see Bitcoin come in. He owns it at$58 ,000,$400 ,000. You think about it, he's got a big paper gain right there. But he wants to keep buying it.
40:14When you think about how much is locked up by the whales, he is single-handedly pushing it from a sentiment standpoint. Issuing a$3 billion convert with 0 % interest, right? You're going to take that all day long, go buy stuff. I would question why you wouldn't just buy one of these ETFs that's literally priced at par versus Dan's point buying something two and a half times. It's on, you know, pretty much buying Bitcoin on leverage. So good, more power to him, but not a way that I would express. Well, wait, wait till the real options market comes in Bitcoin and what that's going to mean for the ability to also see capital eviscerated.
40:45But in the meantime, it leaves micro strategy as the levered play. When you say levered play, I mean, it's almost like a 5x levered play. If you can overlay a Bitcoin chart from September and in micro strategy chart, I mean, Bitcoin's probably up, what, 40 percent? Micro strategies went from$100 a share to$550-ish and is pulled back. So, like, every 5 percent in Bitcoin is seemingly a 5x move in micro strategy. I mean, if you want to play that game, that's the deep end of the pool, Mel. That spread is coming in, though. It's got an$86 billion market cap now. We just said it's near$40 billion in the holdings.
41:19Right. I would say that you have these 2X levered micro strategy single name ETFs pointed out in the Wall Street Journal yesterday. Yeah. And how they're not the reason and they're not matching up because the dealers on Wall Street won't give them the swap capacity they need. And so but it is creating demand in the option market because they can't go on swap. They're going to buy call options and they're not performing like they should. So something to watch out for. Imagine a levered play on a levered play. Sounds like a wonderful idea. As Karen would say in there. Yeah, but really quickly, it's not on the company.
41:48It's on investors willing to pay that because they could go and buy Bitcoin. You can buy ETFs. And, you know, this is a great example of that. I mean, he's taking advantage of that to the point that there's demand for his company based on his, you know, commitment to the idea. It's not the company. It's Bitcoin. That's what I said. Up next, final trades.
42:18time for the final trade let's go around the horn tim at &t and their churn has actually returned to levels of their peers i think you can stay there danny moses amazon black friday football game the only beneficiary wasn't shopping it was the gambling company's genius sports long and strong great to have you on the best danny it was fine damn dude benioff getting right up in microsoft's grill like that i mean that one seems like underperformance not great results I'd stay away from it. It's great having Danny here for Obesity Week. That's good. Thank you guys. No bullying here. And Tesla's all-time high.
42:52Come on. The A in the Klan was on fire today, Mel. What's that? As it sometimes is. On fire. Out. Thanks for watching Fast Money, Mad Money with Jim Kramer starts right now.
43:27Thank you.
43:43To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.
From the publisher
Tariff threats and trade restrictions are the latest irritations in rising U.S/China tensions. But the Chartmaster Carter Worth says now could be the time to get in. What he’s seeing in the technicals, and how your money can fare in the China trade. Plus Fast Money’s special coverage of the weight loss drug space continues. How one biotech company is standing out from the competition, and how its obesity drug could do more than trim your waistline.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
